Nuclide
people

people

The clinicians and scientists doing the work: specialisms, bios, papers, and where to find them.

47 people
A. Oliver Sartor
Professor of Medical Oncology and Urology, Mayo Clinic · Mayo Clinic
Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.
2
Amir Iravani
Associate Professor and Vice Chair of Clinical Research, Director of the Theranostics Program, Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine at UCLA (from July 2026; previously Theranostics Clinical Director, Fred Hutchinson Cancer Center, and Associate Professor of Radiology, University of Washington, 2022-2026)
A nuclear medicine physician-scientist who worked on the practice-changing TheraP and LuPSMA trials in Australia and has moved through Fred Hutchinson to UCLA in 2026 to build a new hospital theranostics programme.
3
Andrei Iagaru
Professor of Radiology (Nuclear Medicine), Stanford University Medical Center (formerly Chief of the Division of Nuclear Medicine and Molecular Imaging, 2016-2026; Stanford's faculty page as of September 2026 lists Erin Grady, MD, as Interim Division Chief)
A Stanford nuclear medicine professor who led the division for a decade and has published widely on new PET tracers, from FAPI scans of fibrosis-related proteins to whole-body PET scanners that image the entire body at once.
3
Chris C. Parker
Clinical oncologist, The Royal Marsden and The Institute of Cancer Research · The Royal Marsden
London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.
2
Clemens Kratochwil
Nuclear medicine physician, Heidelberg University Hospital · Heidelberg University Hospital / NCT / DKFZ
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
1
Dale L. Bailey
Principal Medical Physics Specialist, Department of Nuclear Medicine, Royal North Shore Hospital, Sydney; Professor, Faculty of Medicine and Health, University of Sydney
An Australian medical physicist who helped prove that SPECT scans, not just PET scans, can measure exact amounts of radioactivity in the body, which underpins accurate dosing of radioactive cancer treatments.
3
Declan G. Murphy
Director of Genitourinary Oncology, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre
Urologist who co-led proPSMA, the trial that showed PSMA PET should replace CT and bone scan for staging prostate cancer.
2
Delphine L. Chen
Professor, Clinical Research Division, Fred Hutchinson Cancer Center; Professor of Radiology, University of Washington; Clinical Research Director for Radiology, Fred Hutch (from January 2026; Director of Molecular Imaging and Therapy, Fred Hutch, since 2019)
A Seattle-based nuclear medicine physician-scientist who ran the first human trial of a PET tracer that shows whether a tumour will respond to PARP-inhibitor drugs, and who now directs nuclear medicine and molecular imaging therapy at the Fred Hutchinson Cancer Center.
3
Ebrahim S. Delpassand
Chief Executive Officer and Medical Director, Excel Diagnostics and Nuclear Oncology Center · Excel Diagnostics and Nuclear Oncology Center
The nuclear medicine physician who founded and leads Excel Diagnostics in Houston, a radiopharmaceutical therapy centre that also runs early trials of new radioligands.
0
Emily K. Bergsland
Professor of Medicine; Associate Director for Education, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center
Neuroendocrine tumour specialist who helps design the trials that set treatment for these rare cancers.
3
Erik S. Mittra
Professor of Diagnostic Radiology; Chief, Nuclear Medicine and Molecular Imaging; Director, Radiopharmaceutical Therapeutics, Oregon Health & Science University
A Stanford-trained nuclear medicine doctor who leads the theranostics programme at Oregon Health & Science University and treats neuroendocrine tumour patients with radioactive peptide therapy.
2
Frederik Giesel
Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg · Heidelberg University Hospital / NCT / DKFZ
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
1
Heiko Schöder
Chief, Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center; Professor of Radiology, Weill Cornell Medical College · Memorial Sloan Kettering Cancer Center
A nuclear medicine doctor who runs the molecular imaging service at Memorial Sloan Kettering and has spent years studying how PET scans taken partway through chemotherapy for lymphoma can predict which patients need more or less treatment.
3
Jason S. Lewis
Emily Tow Jackson Chair in Oncology and Chief Attending, Radiochemistry and Imaging Sciences Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Radiochemist who built the zirconium-89 immuno-PET platform and MSKCC's radiopharmaceutical pipeline.
2
Jeremie Calais
Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA · UCLA Jonsson Comprehensive Cancer Center
Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.
2
Johannes Czernin
Chief, Ahmanson Translational Theranostics Division, UCLA · UCLA Jonsson Comprehensive Cancer Center
Nuclear medicine leader who helped bring PSMA PET and radioligand therapy to the United States.
2
Jonathan R. Strosberg
Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center
Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours.
3
Karim Fizazi
Head of Medical Oncology, Gustave Roussy; Professor, Paris-Saclay
Led LATITUDE and PEACE-1, which put abiraterone into first-line metastatic prostate cancer.
4
Katherine K. Matthay
Professor Emerita of Pediatrics, UCSF; Children's Oncology Group neuroblastoma investigator · UCSF Helen Diller Family Comprehensive Cancer Center
Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.
2
Ken Herrmann
Chair of Nuclear Medicine, University Hospital Essen · West German Cancer Center (WTZ), University Hospital Essen
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
2
Lisa Bodei
Attending Physician and Director of Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center; Professor of Radiology, Weill Cornell Medical College
An Italian-trained nuclear medicine doctor who helped develop the lutetium-177 dotatate treatment for neuroendocrine tumours and now leads targeted radionuclide therapy at Memorial Sloan Kettering in New York.
4
Louise Emmett
Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW
Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.
2
Matthias Eiber
Professor and Head of the Theranostics Section, Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich · TUM Klinikum rechts der Isar / CCC München
A German nuclear medicine physician whose 2015 study of gallium-68 PSMA PET scanning for prostate cancer became one of the most-cited papers in the field, and who now leads theranostics research in Munich.
4
Michael Hofman
Professor of Nuclear Medicine; Director, Prostate Cancer Theranostics and Imaging Centre of Excellence · Peter MacCallum Cancer Centre
Led proPSMA and TheraP, the trials that proved PSMA PET beats conventional imaging and that lutetium-PSMA beats chemotherapy.
2
Michael J. Morris
Prostate Cancer Section Head, Genitourinary Oncology Service · Memorial Sloan Kettering Cancer Center
Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.
2
Michael Lassmann
Head of Medical Physics, Department of Nuclear Medicine, University Hospital Würzburg
A German medical physicist who has led the physics section of Würzburg's nuclear medicine department for three decades and helped set the international standards used to calculate radiation doses from radioactive cancer treatments.
2
Neeta Pandit-Taskar
Chief of Nuclear Medicine and Vice-Chair of Clinical and Translational Research, UPMC Hillman Cancer Center / University of Pittsburgh (from July 2025; previously at Memorial Sloan Kettering Cancer Center, 2000-2025)
A nuclear medicine doctor who spent 25 years at Memorial Sloan Kettering developing radioactive antibody treatments, including therapies for children with neuroblastoma, before moving to lead nuclear medicine at UPMC Hillman Cancer Center in 2025.
2
Paola Anna Erba
President (2025-2026) · European Association of Nuclear Medicine
Italian nuclear medicine physician serving as President of the European Association of Nuclear Medicine.
3
Peter Bartenstein
Director, Department of Nuclear Medicine, LMU Munich · LMU Klinikum München
Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.
3
Phillip H. Kuo
Professor and Division Chief of Nuclear Medicine and Director of Theranostics, Department of Diagnostic Radiology, City of Hope Cancer Center (since 2024; previously Chief of Nuclear Medicine, University of Arizona, 2014-2024)
A nuclear medicine physician who helped write the eligibility scans used to select prostate cancer patients for the VISION trial of lutetium-177 PSMA-617, and who also sets national standards for brain PET scans used in Alzheimer's disease.
3
Pierre Vera
Directeur Général (Director General), Centre Henri Becquerel
Nuclear medicine physician who directs Centre Henri Becquerel, the comprehensive cancer centre for the Rouen area in Normandy.
3
Rafael Mariano Grossi
Director General · International Atomic Energy Agency: Rays of Hope
Argentine diplomat leading the IAEA since 2019, whose Rays of Hope initiative expands radiotherapy and nuclear medicine access in low- and middle-income countries.
1
Rahul Aggarwal
Associate Director for Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center
Prostate oncologist studying how tumours transform to escape hormone therapy and how to target them with radioligands.
2
Richard P. Baum
Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt · Curanosticum Wiesbaden-Frankfurt
One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.
3
Robert H. Mach
Britton Chance Professor of Radiology; Director, PET Radiochemistry · Abramson Cancer Center, University of Pennsylvania
Robert Mach invented the PARP PET tracer FluorThanatrace that images DNA repair capacity in tumours.
1
Rodney J. Hicks
Founder, Executive Chairman and Chief Medical Officer, Melbourne Theranostic Innovation Centre; Professor of Medicine, University of Melbourne (previously Director, Centre for Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, until 2021)
An Australian nuclear medicine pioneer who built Peter MacCallum Cancer Centre's molecular imaging and therapy service into a world-renowned unit over three decades, and now runs an independent theranostics centre in Melbourne.
3
Scott T. Tagawa
Professor of Medicine and Urology, and Director of the Genitourinary Oncology Program, Weill Cornell Medicine / NewYork-Presbyterian
A cancer doctor at Weill Cornell in New York who has spent two decades testing PSMA-targeted radioactive treatments for prostate cancer, from the first antibody versions through to lutetium-177 PSMA-617.
3
Shahneen Sandhu
Medical oncologist; Lead, Genitourinary Oncology Theranostics, Peter Mac · Peter MacCallum Cancer Centre
Runs the medical oncology side of Peter Mac's theranostics programme, combining lutetium-PSMA with hormonal and immune therapies.
1
Shaoli Song
Professor and Director, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center · Fudan University Shanghai Cancer Center
Leads the nuclear medicine group behind the first human TROP2 PET imaging, aiming to pick patients for TROP2 ADCs with a scan.
3
Silke Gillessen
Medical and Scientific Director, Oncology Institute of Southern Switzerland (IOSI), Bellinzona
Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide.
2
Simron Singh
Medical Oncologist and Co-Director, Susan Leslie Clinic for Neuroendocrine Tumours, Sunnybrook Odette Cancer Centre
Led NETTER-2, which moved lutetium dotatate into first-line treatment of higher-grade neuroendocrine tumours.
3
Stefano Fanti
Full Professor of Diagnostic Imaging and Director of Nuclear Medicine, University of Bologna / Policlinico Sant'Orsola; Vice Rector for Research, University of Bologna · IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola
An Italian nuclear medicine professor who built one of Europe's busiest PET centres in Bologna and co-writes the international guidelines that tell doctors when and how to use PSMA PET scans in prostate cancer.
3
Thomas A. Hope
Professor of Radiology; Chief of Nuclear Medicine, UCSF · UCSF Helen Diller Family Comprehensive Cancer Center
Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.
2
Uwe Haberkorn
Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ · Heidelberg University Hospital / NCT / DKFZ
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
1
Virginia Pappas
Chief Executive Officer · Society of Nuclear Medicine and Molecular Imaging
Long-serving CEO of the Society of Nuclear Medicine and Molecular Imaging.
0
Wolfgang A. Weber
Chair of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich · TUM Klinikum rechts der Isar / CCC München
Nuclear medicine physician who established PET response criteria and leads Munich's radiopharmaceutical development pipeline.
2
Wolfgang P. Fendler
Professor and Vice Chair (deputy director), Department of Nuclear Medicine, University Hospital Essen / University of Duisburg-Essen · West German Cancer Center (WTZ), University Hospital Essen
A German nuclear medicine doctor at Essen who helped design a scoring system, RECIP, for reading follow-up PSMA scans in prostate cancer patients on lutetium therapy, and who co-writes the field's international imaging guidelines.
3